MODAG GmbH

Privately held: no public share price

Assets

(1 total)
1Total Assets
0Approved
0Phase 3 / Filed
1Phase 1–2 / Early
1Diseases
Showing 1 of 1 assets
Target & Modality
Phase 1
alpha-synuclein oligomersSmall molecule
Parkinson's Disease

Upcoming events

(2 total)

Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2027 (1)
September 2027 (1)
EmrusolminPhase 2Multiple System Atrophy
Est. primary completion 2027-09-15 · NCT06568237 · CT.gov ↗
What to watch
2029 (1)
May 2029 (1)
EmrusolminPhase 2Multiple System Atrophy
Est. primary completion 2029-05-03 · NCT07197866 · CT.gov ↗
What to watch

See the full readout calendar ↗

Regulatory and conference events

(1)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

2 November 2026Topline resultEmrusolminTOPAS-MSA stopped after its interim futility analysis
Teva Pharmaceutical Industries · Source ↗

Financial reports

No financial reports recorded.